Advertisement Investment in Supply Chain Visibility Saves Costs - Pharmaceutical Business review

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Whitepapers

Investment in Supply Chain Visibility Saves Costs

A risk-based approach to monitoring investigational medicinal products (IMP) can help pharmaceutical companies improve supply chain efficiency, but to do this without compromising quality relies on fast access to comprehensive shipment data.

Using cloud temperature monitoring solution CCIS and data loggers from TSS, GlaxoSmithKline has saved £4 million annually.

Director of supply chain logistics at IMP at GSK Rob Montague and CEO of TSS Niclas Ohlsson discuss risk-based approaches to monitoring IMPs and why you should adopt it.